Russell Massine, MD
Nephrology · Bend, ORNPI 1447329032
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 42.6% of the total. Reporting peaked in 2020 at $173 and has fallen 92.2% since, to $14 in 2023.
Across 16 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$135
- Vifor Pharma, Inc.$78
- Daiichi Sankyo Inc.$43
- Otsuka America Pharmaceutical, Inc.$19
- Otsuka Pharmaceutical Development & Commercialization, Inc.$17
- Calliditas Therapeutics US Inc.$14
- plus $12 from 1 others
What the payments were for
- Food & beverage$29192%
- Education$258%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$317 in reported general payments places this provider in the 55th percentile of 120 nephrology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 110 | $150,533 |
| EliquisApixaban | 68 | $81,525 |
| FarxigaDapagliflozin Propanediol | 20 | $28,188 |
| CreonLipase/Protease/Amylase | 17 | $21,695 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $20,414 |
| OzempicSemaglutide | 14 | $14,894 |
| Lanthanum Carbonate | 13 | $11,341 |
| Sevelamer Carbonate | 47 | $6,948 |
| MyrbetriqMirabegron | 11 | $6,832 |
| Potassium Citrate ErPotassium Citrate | 60 | $6,013 |
| Losartan Potassium | 368 | $5,049 |
| Furosemide | 425 | $4,573 |
| Atorvastatin Calcium | 245 | $4,496 |
| Torsemide | 79 | $4,490 |
| Calcium Acetate | 56 | $3,939 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Bend
- Michael FeldmanBend$8K
- Sarah StruthersBend$299
- Neil KumarRoseburg$532K
- Robert ProvenzanoPortland$45K
- Cyril KuriakoseTualatin$36K
- Nayan AroraPortland$23K
- Shalin SanghviSpringfield$20K
- Ramesh MarahattaSpringfield$19K
- Rupali AvasarePortland$16K
- David EllisonPortland$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.